Coeptis Therapeutics Hldgs I
13F holders, Q4 2024 (December 31)2holders −13
0new positions
14sold out
$5.34avg. 13F price*
At the end of Q4 2024, 2 institutions reported holding Coeptis Therapeutics Hldgs I in their 13F filings, down 13 from Q3 2024. 0 opened new positions and 14 sold out. The largest holders were Mint Tower Capital Management B.V. ($12K) and Barclays PLC ($369).
- Company
- Coeptis Therapeutics Hldgs I
- CUSIP
- 19207A108
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 14 | $299K |
All 13F filers, Q3 2024 → Q4 2024: 1,703,891 shares sold, net −1,703,891 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Mint Tower Capital Management B.V. | 0.01% | Reduce -95.0% | 2,250 | $12K |
| Barclays PLC | 0.00% | No change | 67 | $369 |
"% of holder's portfolio" is COEPTIS THERAPEUTICS HLDGS I's weight in each manager's 13F, not the share of Coeptis Therapeutics Hldgs I the manager owns.